About Robb Milne

Bridging the gap between biotechnology and high-tech sectors is critical to helping doctors and patients benefit from advances in technology. Robb Milne is at the center of that effort at Aperiomics. He brings more than 20 years of success as a sales leader, his perspective establishing synergy between the high-tech and biotech industries. Milne is tasked with taking Aperiomics to the next level of success and increasing its visibility so the company can help more people worldwide. Milne serves as a member of the Northern Virginia Technology Council, VirginiaBio and the Northern Virginia Chamber of Commerce.

Biotech Aperiomics Raises $512K in Seed Funding to Further Expand Its Pathogen Testing Services

By | 2017-10-18T00:38:40+00:00 October 18th, 2017|

Ashburn, VA –, October 17, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing the power of deep next-generation sequencing to identify all known pathogens (bacteria, virus, fungi or parasite) in a single test, today announced the latest development in its growth. The company has closed a seed round of funding, raising $512,000, led by Pipeline Angels, a national network of new and seasoned women angel investors.

 

Stacy Manvitz, Pipeline Angels member and Aperiomics board member said “Aperiomics is an excellent example of the type of company Pipeline Angels seeks to support.  Run, in part, by a woman with a mission to grow and expand a business that has a tremendous opportunity for meaningful impact on the quality of life of the people it touches, as well as the ability to push forward innovation and positive change in the medical testing industry.”

 

Chemical Angel Network was also a key investor in this round. The organization provides a mechanism for accredited angel investors to source and vet quality early-stage investment opportunities.  They also assist entrepreneurs and early-stage growth companies as a source for quality information.

 

Executive director and co-founder Mark Vreeke said “Chemical Angel Network is excited to participate in this round. It is rare that you see such an early stage life science company capable of producing significant revenue.”

 

“Aperiomics is growing quickly and we are working hard to help healthcare providers get information never possible before our technology,” said company CEO and co-founder Dr. Crystal Icenhour. “We are excited about this new funding. It is a strong vote of confidence in our team and our mission.”

 

This has been a big year for Aperiomics. Focused on integrative health providers and private practice physicians, the company has grown its customer base more than ten-fold during 2017. With each customer (or doctor) representing multiple patients, the company has seen a dramatic increase in the number of patients it serves. Revenue over the first six months alone was higher than the entirety of the company’s revenue since it began operations in 2014. The company also expanded its staff, including a director of sales and marketing, to scale growth.

 

Recognizing the innovation of its work early on, the National Science Foundation (NSF) has been a strong supporter with $1.6 million in grants to the company to date. An additional NSF research grant is expected and will in part seek fund efforts to improve the cost efficiency of the DNA sequencing process.  This combined funding puts Aperiomics on solid footing to actively pursue grow strategies to scale its business and fulfill its mission to help find answers for more people with unknown or misdiagnosed illnesses.

 

About Aperiomics

 

The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test. Clinicians and patients call on Aperiomics to aid in the identification of infectious diseases that other tests cannot identify or would require a multitude of tests and an idea of what to look for. Through next-generation sequencing of the DNA or RNA in a sample, a complete genetic fingerprint is created and run through a proprietary data analysis algorithm to profile the entire sample. The Aperiomics Microbial Database™- is the most comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others.  Aperiomics was named Life Sciences Innovators of the year in 2016 and a finalist in the 2017 Greater Washington Innovation Awards.  For more information, visit www.aperiomics.com or call (703) 229-0406.

 

Aperiomics Adds Jason Zhang to Team as Software Engineer

By | 2017-08-28T16:03:01+00:00 August 28th, 2017|

Jason Zhang

Ashburn, VA – August 28, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing the power of next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test, today announced that Jian “Jason” Zhang has joined the company as a software engineer.

Jason joins the research and development division of Aperiomics with strong experience as a web developer, software project manager and software engineer. Before Aperiomics, he launched a number of major successful commercial websites and he is fluent in all of the major programming languages – Java, JavaScript, Typescript, Python, Ruby and others. He is also an expert in full-stack web development, especially in AngularJS, Angular2, Rails and Django frameworks.

“This is an exciting time for Aperiomics. Jason is the third member of the team announced since last month as we continue to grow,” said company CEO Dr. Crystal Icenhour. “We’ve built a team of highly skilled world-class technologists, making our services indispensible to the medical community and the patients they serve.”

Jason earned his M.S. degree in information technology from Virginia Polytechnic Institute and State University, and an M.A. degree in human resources management from Michigan State University.

In his spare time, Zhang is an avid athlete and sports fan. In 2004 he was among the torch runners during the 2004 Athens Olympics Games. He regularly participates in regional 5K and 10K races as well as open-water swimming competitions. Jason is training for his first triathlon later this year. He was an athlete in high school and college and won several provincial collegiate championship titles in track and field including the 110-meter hurdles. He still holds a track record at Jinan University in China.

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test.  Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.).  The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others.  Aperiomics was named among Life Sciences Innovators in 2016 and a finalist in the 2017 Greater Washington Innovation Awards.

For more information, visit www.aperiomics.com or call (703) 229-0406.

Aperiomics Names Alvin Chen, PhD Chief Technology Officer

By | 2017-08-24T18:09:58+00:00 August 8th, 2017|

Ashburn, VA – August 8, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing the power of next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test, today announced that Alvin (Yuan) Chen, PhD, has been named the company’s chief technology officer.

Dr. Chen has more than 10 years experience in next-generation sequencing and is an expert in genomics, genetics and bioinformatics. Dr. Chen joined Aperiomics in 2015 and served as PI of the an NSF SBIR Phase II grant. He successfully developed the company’s primary platform, Xplore-NGS™, which uses DNA sequencing technology to identify all microbes in a single test. He also leads the development of the company’s information management systems.

“Alvin is among the best innovators in the world of next-generation sequencing and we’re very pleased that he is leading our technology efforts,” said company CEO Dr. Crystal Icenhour.  “He has made a strong mark on our company and the customers we serve, constantly improving the way we help clinicians and patients identify the causes of infectious diseases.”

Dr. Chen has provided leadership in a number of scientific research projects, and has produced more than 15 publications in high-impact, peer-reviewed journals, such as PLoS Genetics, Genome Research, MBio, Nature Communications and Molecular Ecology.  He is a passionate programmer with more than 25 years of experience, leading and participating in multiple software development projects. He is proficient in many different programming languages and hardware and system architecture.

Dr. Chen received his Ph.D. from the Graduate University of Chinese Academy of Sciences in 2012 and then joined the Division of Infectious Diseases at Duke University Medical Center as a Postdoc Fellow from 2012-2015.  He is an amateur photographer, sports enthusiast and avid outdoorsman.

 

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test.  Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify.  The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.).  The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others.  Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards.

For more information, visit www.aperiomics.com or call (703) 229-0406.

Biotechnology Company Aperiomics Launches New Website

By | 2017-09-04T18:06:47+00:00 August 1st, 2017|

Original article: http://citybizlist.com/article/433201/biotechnology-company-aperiomics-launches-new-website

Ashburn, VA – August 1, 2017 –Aperiomics, a biotechnology company that saves lives by harnessing next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test to pinpoint the causes of infectious disease, today launched its new website – http://www.aperiomics.com — an information portal for clinicians, patients and researchers.

Aperiomics is one of the rising stars of the biotech industry. The company is growing quickly and has drawn attention not only of the medical industry but investors as well. Over the first six months of 2017, Aperiomics grew its customer base ten-fold. Revenue over the same period alone was higher than the entirety of the company’s revenue since it started in 2014. Aperiomics has received more than $1.6 million in grants from the National Science Foundation – the latest, a grant to further develop its pathogen identification platform.

Among customers that Aperiomics has helped are hundreds of patients for whom doctors could not find a solution to their illnesses until their samples were analyzed by Aperiomics to detect which pathogens were responsible. For some it was a life-death issue. Americans spend $200-250 billion per year on medical diagnostic testing according to the American College of Physicians. Much of that testing uses old technology and guesswork, leading to wasted time, money and chronic infection.

“Aperiomics is at the forefront of a very exciting worldwide expansion of technology in medicine,” said company CEO Dr. Crystal Icenhour. “Because of our powerful technology and the expert team we have in place, medical professionals and patients put their confidence in Aperiomics to find answers that no one else can find.”

The new Aperiomics website provides specific information on services for clinicians, patients and researchers:

  • For clinicians, Aperiomics solves inadequate pathogen testing by using deep next-generation sequencing and the Aperiomics Microbial Database™ (the world’s largest collection of pathogens) to test for everything instead of only a few things at a time.
  • For patients, Aperiomics can help their doctors provide faster wellness through more accurate identification of the causes of infectious diseases.
  • For researchers, next-generation sequencing and bioinformatic services can be customized for all pathogen testing and microbiome characterization work. Aperiomics has worked with many organizations to support genetic monitoring, biosurveillance, pathogen identification, microbiome characterization and quality monitoring programs.

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.

Aperiomics Names Robb Milne Director of Sales and Marketing

By | 2017-08-24T18:13:21+00:00 August 1st, 2017|

Ashburn, VA – August 1, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing the power of next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test, today announced that Robb Milne has joined the company as Director of Sales and Marketing.
Milne brings to Aperiomics more than 20 years of success as a sales leader, his perspective establishing synergy between the high-tech and biotech industries. He is tasked with taking Aperiomics to the next level of success and increasing visibility so the company can help more people worldwide. Most recently, he guided creation of the company’s new website, an information portal for clinicians, patients and researchers.

Director of Sales and Marketing

Robb Milne

Over his career, Milne has been ranked a top sales executive at a number of high tech companies including Logi Analytics, ApeSoft and Sage. He also serves as a member of the Northern Virginia Technology Council, VirginiaBio and the Northern Virginia Chamber of Commerce.

“We’re very excited to have someone with Robb’s strong experience and skills on the team,” said company CEO Crystal Icenhour. “As we move forward, he is in charge of expanding our reach to all of our audiences including the medical industry and patients themselves using a wide variety of media and methods. The services that Aperiomics provides are unique in the world and the faster we get word out about them, the more people we will be able to help.”

Milne holds a bachelor of arts degree in communications/public relations from George Mason University in Fairfax, VA, and has completed training with a number of nationally recognized sales organizations including Dale Carnegie Sales Advantage, Xerox Document University Sales, the Sandler High-Tech Selling System Training and Skip Miller’s Proactive Sales Training.

About Aperiomics
Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards.

For more information, visit www.aperiomics.com or call (703) 229-0406.

 

Aperiomics Launches New Website as Information Portal for Clinicians, Patients and Researchers

By | 2017-08-29T16:44:52+00:00 July 31st, 2017|

Ashburn, VA – July 31, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test to pinpoint the causes of infectious disease, today launched its new website – http://www.aperiomics.com — an information portal for clinicians, patients and researchers.

Aperiomics is one of the rising stars of the biotech industry. The company is growing quickly and has drawn attention not only of the medical industry but investors as well. Over the first six months of 2017, Aperiomics grew its customer base ten-fold. Revenue over the same period alone was higher than the entirety of the company’s revenue since it started in 2014. Aperiomics has received more than $1.6 million in grants from the National Science Foundation – the latest, a grant to further develop its pathogen identification platform.

Among customers that Aperiomics has helped are hundreds of patients for whom doctors could not find a solution to their illnesses until their samples were analyzed by Aperiomics to detect which pathogens were responsible.  For some it was a life-death issue.  Americans spend $200-250 billion per year on medical diagnostic testing according to the American College of Physicians. Much of that testing uses old technology and guesswork, leading to wasted time, money and chronic infection.

“Aperiomics is at the forefront of a very exciting worldwide expansion of technology in medicine,” said company CEO Dr. Crystal Icenhour.  “Because of our powerful technology and the expert team we have in place, medical professionals and patients put their confidence in Aperiomics to find answers that no one else can find.”

The new Aperiomics website provides specific information on services for clinicians, patients and researchers:

  • For clinicians, Aperiomics solves inadequate pathogen testing by using deep next-generation sequencing and the Aperiomics Microbial Database™ (the world’s largest collection of pathogens) to test for everything instead of only a few things at a time.
  • For patients, Aperiomics can help their doctors provide faster wellness through more accurate identification of the causes of infectious diseases.
  • For researchers, next-generation sequencing and bioinformatic services can be customized for all pathogen testing and microbiome characterization work. Aperiomics has worked with many organizations to support genetic monitoring, biosurveillance, pathogen identification, microbiome characterization and quality monitoring programs.

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test.  Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify.  The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.).  The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others.  Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards.  For more information, visit www.aperiomics.com or call (703) 229-0406.

Aperiomics Mentioned in “Technically DC”

By | 2017-09-05T20:40:52+00:00 July 26th, 2017|

Original article: https://cbi.gwu.edu/aperiomics-mentioned-technically-dc

July 26, 2017

Aperiomics, a spin-off company from a joint venture between Professor Keith Crandall, Director of the Computational Biology Institute, and The George Washington University, was mentioned in “Technically DC” on June 28th, 2017. Their participation in DC I-Corps, a National Science Foundation-funded regional program sponsored by a consortium from George Washington University, University of Maryland College Park, Virginia Tech and John Hopkins University. In the program, teams focus on the customer discovery process, and use applied research to find market viability upfront.

To read the article, click here.

To learn more about Aperiomics, click here.

Aperiomics to present at Cavendish Global Health Impact Forum

By | 2017-09-06T21:12:05+00:00 May 5th, 2017|

Original article: https://www.vabio.org/news/news.asp?id=344198

Friday, May 5, 2017

Virginia Bio member, Aperiomics, a biotech company that has created a unique technology to revolutionize the diagnosis of infectious disease, has been selected to present at the Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio). The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Aperiomics’ research and scientific insights in the diagnosis of infectious disease positions them to make a major contribution in creating better clinical outcomes, preventing and containing epidemics, and limiting the development of antibiotic-resistant “super bugs”.

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to quickly and accurately identify any known pathogen from a single test. The effects of this novel technology will be felt around the world as health care providers are enabled to quickly diagnose and properly treat diseases afflicting human and animal populations around the world,” said Crystal Icenhour, PhD and CEO of Aperiomics and Virginia Bio Chariman. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

Aperiomics Selected to Participate at Upcoming Cavendish Global Health Impact Forum

By | 2017-09-21T19:48:56+00:00 May 5th, 2017|

Sterling, VA, May 5, 2017Aperiomics, a biotech company that has created a unique technology to revolutionize the diagnosis of infectious disease, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio). The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact nvestors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Aperiomics’ research and scientific insights in the diagnosis of infectious disease positions them to make a major contribution in creating better clinical outcomes, preventing and containing epidemics, and limiting the development of antibiotic-resistant “super bugs”.

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to quickly and accurately identify any known pathogen from a single test. The effects of this novel technology will be felt around the world as health care providers are enabled to quickly diagnose and properly treat diseases afflicting human and animal populations around the world,” said Crystal Icenhour, PhD and CEO of Aperiomics. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

 

About Aperiomics

Based in Sterling, VA, Aperiomics was founded in October 2013 as a spinoff from the Computational Biology Institute at George Washington University’s Virginia Science and Technology Campus in Sterling.  The company combines genomics and informatics in an innovative way to produce faster and more accurate results than culture-based or even other molecular-based diagnostic approaches.

From a single test, Aperiomics can simultaneously test for all pathogens whether bacteria, virus, fungus or parasite. The sample can be tissue, plant, animal, or environmental.  Based on its unique process that capitalizes on high-throughput Next-generation sequencing and advanced Bayesian statistics, Aperiomics can not only find a “needle in a haystack” but can also reveal that a “needle” is lurking there – even if it is a formerly unknown pathogen.  This effective system translates into improved human and animal health, reduced risk to public health, and significant health care cost savings.

Further information is available on the Company’s website, www.aperiomics.com.

 

About Cavendish Global

(http://cavendishglobal.com)

Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation. Cavendish will host Forums in 2017 in Washington, DC, Chicago and Boston.

For more information: http://cavendishglobal.com

 

For Further Information, Contact:

Ian Kenyon

Director, Corporate Communications

Ian.Kenyon@CavendishGlobal.com

 

Aperiomics Brings Pathogen Testing to Integrative Healthcare Field

By | 2017-08-29T16:05:04+00:00 May 2nd, 2017|

Original article: http://www.clpmag.com/2017/05/aperiomics-brings-pathogen-testing-integrative-healthcare-field/

Ashburn, VA – May 2, 2017 — Aperiomics recently introduced its infectious disease diagnostic services to the integrative healthcare field at the annual Integrative Healthcare Symposium in New York City.

With a single test of any biological sample, Aperiomics seeks to accurately identify all microbes present—including pathogens—whether bacteria, fungus, parasite, or virus. The single test can ensure correct and comprehensive pathogen identification for better patient outcomes, monitor animal populations and environments for potential outbreaks, limit development of antibiotic-resistant ‘superbugs,’ and maintain the safety of food-processing and water systems, among other applications.

“Our goal is to completely change the way the world identifies microorganisms, to improve health for humans and animals,” says Crystal Icenhour, PhD, CEO of Aperiomics. “Currently, up to 75% of infections are never diagnosed. Antibiotics are overused partly because of this inability to achieve diagnosis and partly through prophylactic use in food production. This misuse is creating resistant pathogens for which we presently have no effective treatments.”

Icenhour adds, “It’s worth noting that more-effective healthcare will not only produce better patient outcomes, but can also greatly reduce healthcare expenses. We’re driven to help people by enabling our clients to make better, more informed decisions.”

Instead of traditional laboratory testing that requires a suspected target, the Aperiomics system combines genomics and informatics in a novel way, intended to produce faster and more accurate results than culture-based or even other molecular-based diagnostic methods. The system uses unbiased high-throughput next-generation sequencing with a proprietary advanced statistical analysis not only to find a ‘needle in a haystack’ but also to reveal that a pathogenic ‘needle’ is lurking there even before the pathogen has caused symptoms.

Currently, Aperiomics offers two services. Xplore-Patho is a service that allows practitioners to send a biological sample to Aperiomics for analysis to identify all known pathogens in the sample. Xplore-Biome characterizes the microbiome of any given sample.

“The next Aperiomics product will be a service to test for a pathogen’s drug resistance,” says Robb Milne, director of sales and marketing at Aperiomics. “Another future application will be a method, already demonstrated in an academic setting, to discover previously unknown pathogens.”

For more information, visit Aperiomics.